- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT02893865
Evolution of Oxidative Stress in Coronary Patients With Moderate Sleep Apnea Syndrome After Treatment With Continuous Positive Airway Pressure (CardioX SAS)
Published data indicate that obstructive sleep apnea syndrome (OSAS) worse the prognosis of coronary artery disease (CAD) and that oxidative stress can link this 2 diseases.
Investigators hypothesise that oxidative stress decrease after 3 months of continuous positive airway pressure (CPAP) in this specific population.
The results may have major implication in the comprehension of physiopathologic processes linking OSAS and CAD and in the treatment of OSAS in this specific population.
Tutkimuksen yleiskatsaus
Tila
Yksityiskohtainen kuvaus
Obstructive sleep apnea syndrome (OSAS) is a common disorder characterized by recurrent upper airway collapse during sleep and has been associated with worsened prognosis in patients with coronary artery disease (CAD). Moderate OSAS can be defined by an apnea hypopnea index (AHI) between 15 and 30 events/hour.
Pathophysiologic processes are complex and it seems that oxidative stress play and important role. Studies showed that continuous positive airway pressure (CPAP) influence oxidative stress but the results are conflicting.
Moreover there are uncertainties whether diagnosing and treating OSAS can influence the pathophysiological and clinical outcomes in patients with CAD.
Therefore, we aim to test the effects of 3 months of CPAP on systemic redox balance evaluated by plasma GSH/GSSG ratio.
Patients with moderate OSAS will be randomized for the intervention.
Patients with AHI <15/h or >30/h will be included in an ancillary study (blood and urinary test, MIBG scintigraphy) to characterize the biological profile of coronary patients based on their AHI.
For a alpha threshold of 5% and a study power of 80%, the study should include 16 patients in each group. Taking in account a possible 20% of dropout the study will need to include 20 patients by randomized arm to demonstrate an effect.
Opintotyyppi
Ilmoittautuminen (Todellinen)
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Opiskelupaikat
-
-
-
Montpellier, Ranska, 34295
- CHU of MONTPELLIER
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- Apnea Hypopnea Index 15-30/h
- Stable Coronary artery disease
- Obligation of obtaining informed consent form
Exclusion Criteria:
- Heart failure with LVEF less than or equal to 45%
- Other Chronic disease: renal failure, COPD Index - central apneas than or equal to 50% of the total IAH
- treatment with CPAP or mandibular advancement device
- IMC> 40 kg / m²
- Nutritional supplementation in the 4 weeks preceding the study (antioxidants, vitamins ...).
- Treatment with allopurinol or N-acetylcysteine, in the 4 weeks preceding the study.
- PaCO2> 45 mmHg - Counter-indication to the use of PPC: bullous lung disease, pathological hypotension, bypass airway, pneumothorax, signs of sinus infections or inner ear
- Exclusion period on subject compared to another protocol or for which the maximum annual amount of compensation of € 4,500 has been reached.
- Participation of the subject to another study.
- Not affiliated with a social security scheme subject or not the beneficiary of such a regime.
- Pregnant or breastfeeding women, patient unable to give consent, protected adult, vulnerable
- Subject deprived of liberty by judicial or administrative decision
- HIV infection, hepatitis B or hepatitis C known
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Kaksinkertainen
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
---|---|
Kokeellinen: Experimental
Continuous positive airway pressure Patients will receive continuous positive airway pressure during three months
|
Continuous positive airway pressure treatment during three months with adherence recording
|
Huijausvertailija: Sham Comparator
Sham-continuous positive airway pressure Patients will receive sham-continuous positive airway pressure during 3 months
|
Valhe-jatkuva positiivinen hengitysteiden paine kolmen kuukauden ajan kiinnittymisrekisteröinnillä
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Percentage change of serum GSH/GSSG ratio
Aikaikkuna: at the inclusion and the end (3 months) of the study
|
Blood test
|
at the inclusion and the end (3 months) of the study
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Change, after 3 months, of the SOD (parameter of serum oxidative stress level)
Aikaikkuna: at the inclusion and the end (3 months) of the study
|
at the inclusion and the end (3 months) of the study
|
|
Change, after 3 months, of the catalase (parameters of serum oxidative stress level)
Aikaikkuna: at the inclusion and the end (3 months) of the study
|
at the inclusion and the end (3 months) of the study
|
|
Change, after 3 months, of the Vit C and E (parameters of serum oxidative stress level)
Aikaikkuna: at the inclusion and the end (3 months) of the study
|
at the inclusion and the end (3 months) of the study
|
|
Change, after 3 months, of the isoprostanes (parameter of serum oxidative stress level)
Aikaikkuna: at the inclusion and the end (3 months) of the study
|
at the inclusion and the end (3 months) of the study
|
|
Change, after 3 months, of the 8OHDG (other parameters of serum oxidative stress level)
Aikaikkuna: at the inclusion and the end (3 months) of the study
|
by blood test
|
at the inclusion and the end (3 months) of the study
|
Change, after 3 months, of the GPX (parameter of serum oxidative stress level)
Aikaikkuna: at the inclusion and the end (3 months) of the study
|
at the inclusion and the end (3 months) of the study
|
|
Change, after 3 months, of the inflammation parameters: IL6, IL8, TNF α (blood test)
Aikaikkuna: at the inclusion and the end (3 months) of the study
|
at the inclusion and the end (3 months) of the study
|
|
Change, after 3 months, of the urinary catecholamines by urine test
Aikaikkuna: at the inclusion and the end (3 months) of the study
|
at the inclusion and the end (3 months) of the study
|
|
Change, after 3 months, of the MIBG scintigraphy
Aikaikkuna: at the inclusion and the end (3 months) of the study
|
at the inclusion and the end (3 months) of the study
|
|
Change, after 3 months, of the endothelial function (endoPat)
Aikaikkuna: at the inclusion and the end (3 months) of the study
|
at the inclusion and the end (3 months) of the study
|
|
Change, after 3 months, of the blood pressure
Aikaikkuna: at the inclusion and the end (3 months) of the study
|
24h ambulatory blood pressure monitoring
|
at the inclusion and the end (3 months) of the study
|
Change, after 3 months, of the quality of life by the SF 36 questionnaire
Aikaikkuna: at the inclusion and the end (3 months) of the study
|
at the inclusion and the end (3 months) of the study
|
|
Change, after 3 months, of the quality of sleep by PSQI questionnaire
Aikaikkuna: at the inclusion and the end (3 months) of the study
|
at the inclusion and the end (3 months) of the study
|
|
Change, after 3 months, of the sleepiness by the Epworth scale
Aikaikkuna: at the inclusion and the end (3 months) of the study
|
at the inclusion and the end (3 months) of the study
|
|
Change, after 3 months, of the physical activity by the Voorips questionnaire
Aikaikkuna: at the inclusion and the end (3 months) of the study
|
at the inclusion and the end (3 months) of the study
|
Yhteistyökumppanit ja tutkijat
Sponsori
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Todellinen)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Arvio)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
- Patologiset prosessit
- Sydänsairaudet
- Sydän-ja verisuonitaudit
- Verisuonisairaudet
- Hermoston sairaudet
- Hengityselinten sairaudet
- Valtimotauti
- Valtimon tukossairaudet
- Hengityshäiriöt
- Unihäiriöt, luontaiset
- Dyssomniat
- Uniherätyshäiriöt
- Sairaus
- Merkit ja oireet, Hengityselimet
- Sepelvaltimotauti
- Sydänlihaksen iskemia
- Sepelvaltimotauti
- Uniapnea-oireyhtymät
- Oireyhtymä
- Apnea
Muut tutkimustunnusnumerot
- UF 9542
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .
Kliiniset tutkimukset Sepelvaltimotauti
-
Hospital Clinic of BarcelonaAstraZenecaValmisPotilaat, joille on määrä tehdä PCI (Percutaneous Coronary Intervention) CTO (krooninen kokonaistukkos)Espanja
Kliiniset tutkimukset Valhe-jatkuva positiivinen hengitysteiden paine
-
University Hospital, MontpellierTuntematonObstruktiivinen uniapnea-oireyhtymä | AivoinfarktiRanska
-
University of California, San FranciscoRekrytointiMunasarjojen monirakkulaoireyhtymä | Obstruktiivinen uniapneaYhdysvallat
-
Santa Casa de VotuporangaValmisKeuhkokuume | Pleuraeffuusio | AtelektaasiBrasilia
-
Marya Strand, MDValmis
-
University of CalgaryAlberta Health services; Alberta Hip and Knee ClinicRekrytointiKipu, Leikkauksen jälkeinen | Analgesia | Polven nivelrikkoKanada